{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T09:33:52Z","timestamp":1776332032351,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Stroke and Cerebrovascular Diseases"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jstrokecerebrovasdis.2017.06.052","type":"journal-article","created":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T17:15:22Z","timestamp":1501175722000},"page":"2769-2777","source":"Crossref","is-referenced-by-count":5,"title":["Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project"],"prefix":"10.1016","volume":"26","author":[{"given":"Haralampos","family":"Milionis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Ntaios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasileios","family":"Papavasileiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Spengos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efstathios","family":"Manios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moses","family":"Elisaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Vemmos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0010","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1161\/STROKEAHA.111.641381","article-title":"Duration of diabetes and risk of ischemic stroke: the Northern Manhattan Study","volume":"43","author":"Banerjee","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0015","article-title":"Diabetes and stroke prevention: a review","volume":"2012","author":"Hewitt","year":"2012","journal-title":"Stroke Res Treat"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy\u2014I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration","volume":"308","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0030","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s11606-011-1757-y","article-title":"Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis","volume":"26","author":"Simpson","year":"2011","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment","volume":"24","author":"Adams","year":"1993","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0040","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/hs1201.100209","article-title":"Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study","volume":"32","author":"Kolominsky-Rabas","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0045","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S0140-6736(99)04407-4","article-title":"Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations","volume":"354","author":"Hankey","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0050","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/jnnp.60.2.197","article-title":"Aspirin at any dose above 30\u2009mg offers only modest protection after cerebral ischaemia","volume":"60","author":"Algra","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0055","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0060","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.arcmed.2011.09.001","article-title":"Clopidogrel vs. aspirin treatment on admission improves 5-year survival after a first-ever acute ischemic stroke. Data from the Athens Stroke Outcome Project","volume":"42","author":"Milionis","year":"2011","journal-title":"Arch Med Res"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0065","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0070","article-title":"Diabetes mellitus and cardiovascular prevention: the role and the limitations of currently available antiplatelet drugs","volume":"2011","author":"Tufano","year":"2011","journal-title":"Int J Vasc Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0075","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.1538-7836.2004.00836.x","article-title":"Platelet activation in type 2 diabetes mellitus","volume":"2","author":"Ferroni","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0080","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.jacc.2007.11.080","article-title":"The role of aspirin in cardiovascular prevention: implications of aspirin resistance","volume":"51","author":"Gasparyan","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0085","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00125-007-0898-3","article-title":"Aspirin resistance and diabetes mellitus","volume":"51","author":"Ajjan","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0090","doi-asserted-by":"crossref","DOI":"10.5414\/CP202637","article-title":"Prevalence of aspirin resistance in patients with type II diabetes: a descriptive-analytical study","author":"Eskandarian","year":"2017","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0095","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1007\/s00415-016-8181-5","article-title":"Antiplatelet drug resistance is associated with early neurological deterioration in acute minor ischemic stroke in the Chinese population","volume":"263","author":"Yi","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0100","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-2125.2011.03949.x","article-title":"Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?","volume":"72","author":"Ma","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1517\/17425255.2014.856883","article-title":"Antiplatelet drug interactions with proton pump inhibitors","volume":"10","author":"Scott","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0110","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.amjcard.2004.05.032","article-title":"Mortality rates and hemorrhagic complications in Asian-Pacific Islanders during treatment of acute myocardial infarction","volume":"94","author":"Kuo","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0115","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.289.22.2947","article-title":"Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial","volume":"289","author":"Gorelick","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0120","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/CRD.0b013e31815685fa","article-title":"Epidemiology of atherothrombotic disease and the effectiveness and risks of antiplatelet therapy: race and ethnicity considerations","volume":"16","author":"Saunders","year":"2008","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0125","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ahj.2008.08.031","article-title":"Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study","volume":"157","author":"Mak","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0130","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(97)04010-5","article-title":"CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0135","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","article-title":"Profile and prevalence of aspirin resistance in patients with cardiovascular disease","volume":"88","author":"Gum","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0140","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jacc.2004.09.067","article-title":"Variability in platelet responsiveness to clopidogrel among 544 individuals","volume":"45","author":"Serebruany","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0145","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0002-9149(02)02567-5","article-title":"Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus","volume":"90","author":"Bhatt","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0150","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1001\/archinte.164.19.2106","article-title":"Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies","volume":"164","author":"Hirsh","year":"2004","journal-title":"Arch Intern Med"},{"issue":"Suppl 1","key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0155","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/ccd.21995","article-title":"Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?","volume":"74","author":"Mohler","year":"2009","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.06.052_bib0160","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.thromres.2013.12.002","article-title":"Clopidogrel high-on-treatment platelet reactivity in acute ischemic stroke patients","volume":"133","author":"Meves","year":"2014","journal-title":"Thromb Res"}],"container-title":["Journal of Stroke and Cerebrovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052305717303488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052305717303488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T23:20:52Z","timestamp":1535584852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1052305717303488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S1052305717303488"],"URL":"https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2017.06.052","relation":{},"ISSN":["1052-3057"],"issn-type":[{"value":"1052-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}